Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
OwnerTakuya Tamatani, Katsunari Tezuka +2inventors
InventorsTakuya Tamatani, Katsunari Tezuka, Shinji Sakamoto, Masaharu Takigawa
Life of this patent
Estimating the term…
Abstract
A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses thereof; and various monoclonal antibodies having various characteristics against various mammalian CTGFs useful for detecting and assaying CTGFs present in body fluids of mammals suffering from various diseases.
Claims82
A monoclonal antibody or a portion thereof, comprising a property in any of (a) to (g) below:
- (a) reactive to human, mouse and rat connective tissue growth factors (CTGFs);
- (b) reactive to both human and mouse CTGFs but not reactive to rat CTGF;
- (c) reactive to both mouse and rat CTGFs but not reactive to human CTGF;
- (d) inhibiting binding of human CTGF to human kidney-derived fibroblast cell line 293-T (ATCC CRL1573), or the binding of mouse CTGF to said cell line 293-T;
- (e) inhibiting binding of human CTGF to any cells of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570), human osteosarcoma-derived cell line MG-63 (ATCC CRL-1427), or human lung-derived fibroblasts;
- (f) inhibiting cell proliferation of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570)induced by a stimulus with human or mouse CTGF;
- or,
- (g) inhibiting an increase of hydroxyproline in the kidney, wherein said hydroxyproline level tends to be elevated.
A human monoclonal antibody or a portion thereof, reactive to any human, mouse or rat CTGF.
A human monoclonal antibody or a portion thereof, reactive to human CTGF and comprises a property in any of (a) to (d) below:
- (a) inhibiting binding of human CTGF to human kidney-derived fibroblast cell line 293-T (ATCC CRL1573);
- (b) inhibiting binding of human CTGF to any of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570), human osteosarcoma-derived cell line MG-63 (ATCC CRL-1427), or human lung-derived fibroblasts;
- (c) inhibiting the cell proliferation of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570) induced by a stimulus with human or mouse CTGF;
- or,
- (d) inhibiting an increase of hydroxyproline in kidney, wherein said hydroxyproline level tends to be elevated.
A monoclonal antibody or a portion thereof, reactive to human CTGF, which is produced by a hybridoma identified by an international deposit accession No. FERM BP-6535.
A monoclonal antibody or a portion thereof, reactive to human CTGF and comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by an international deposit accession No. FERM BP-6535.
A monoclonal antibody or a portion thereof, reactive to human CTGF, which is produced by a hybridoma identified by an international deposit accession No. FERM BP-6598.
A monoclonal antibody or a portion thereof, reactive to human CTGF and comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by an international deposit accession No. FERM BP-6598.
A monoclonal antibody or a portion thereof, reactive to human CTGF, which is produced by a hybridoma identified by an international deposit accession No. FERM BP-6599.
A monoclonal antibody or a portion thereof, reactive to human CTGF and comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by an international deposit accession No. FERM BP-6599.
A monoclonal antibody or a portion thereof, reactive to human CTGF, which is produced by a hybridoma identified by an international deposit accession No. FERM BP-6600.
A monoclonal antibody or a portion thereof, reactive to human CTGF and comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by an international deposit accession No. FERM BP-6600.
A monoclonal antibody or a portion thereof, reactive to rat CTGF.
The antibody-immobilized insoluble carrier according to 42, wherein said insoluble carrier is selected from the group consisting of plates, test tubes, tubes, beads, balls, filters and membranes.
The antibody-immobilized insoluble carrier according to 42, wherein said insoluble carrier is a filter or membrane, or that used for affinity column chromatography.
A transgenic mouse in which DNA encoding human CTGF is integrated into an endogenous gene locus.
A rat CTGF comprising an amino acid sequence of, or substantially equivalent to an amino acid sequence of SEQ ID NO:
- 2.
A DNA encoding a rat CTGF comprising the amino acid sequence of SEQ ID NO:
- 2.
A pharmaceutical composition for treating or preventing a kidney disease, comprising a CTGF inhibitor or an agent for inhibiting CTGF production, and a pharmaceutically acceptable carrier.
A pharmaceutical composition for inhibiting proliferation of cells in kidney which are capable of proliferating by a stimulus with CTGF, comprising a substance having an activity of inhibiting proliferation of said cells and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.